aTyr Pharma, Inc. has partnered with the Foundation for Sarcoidosis Research for this clinical trial exploring a new treatment.

The purpose of this study is to determine if the investigational drug, ATYR1923, is safe and tolerable in patients with pulmonary sarcoidosis. This study will explore whether ATYR1923 has the potential to reduce oral corticosteroid use, as well as the effects ATYR1923 may have on pulmonary sarcoidosis by FDG-PET/CT, lung function, and biomarkers.

Patients who are eligible for the study will receive a dose of study drug (placebo or ATYR1923) once every 4 weeks intravenously (through an IV) for approximately 5 months (a total of 6 doses). The study drug dose received will depend on which study group the participant belongs.

The study drug and the required examinations and procedures during the study are at no cost to you. Travel reimbursement for the initial screening and all study visits may be provided. Please contact study coordinators for more information.
Researchers are looking for patients that meet the following characteristics:

- Adults living in the United States ages 18-70.
- Biopsy-proven diagnosis of pulmonary sarcoidosis for greater than or equal to 6 months. Patients may also have skin or eye involvement.
- Patients with symptomatic or active disease based on pulmonary function tests, FDG-PET/CT scan, and an evaluation of the shortness of breath you experience.
- Be on a stable dose of 10-25 mg/day oral prednisone or similar medication.
- Weight between 45 kg (approximately 100 pounds) and 160 kg (approximately 352 pounds.)

Please note that if you qualify and are selected for the study you must be able to visit the study site every 2 weeks for the first month and then at least every four weeks for a 6-month period. Travel reimbursements are available for qualifying patients.

Study details and additional information is available on clinicaltrials.gov (NCT03824392) or contact aTyr Pharma Clinical Research:

(877) 215-5731
clinicaltrials@atyrpharma.com

LOCATIONS
Albany, NY
Atlanta, GA
Birmingham, AL
Charleston, SC
Chicago, IL
Cincinnati, OH
Cleveland, OH
Dallas, TX
Denver, CO
Falls Church, VA
Greenville, NC
Iowa City, IA
Philadelphia, PA

Locations may change. Information is updated on clinicaltrials.gov (NCT03824392) once a study site is open for enrollment. Contact study coordinators for more information.

Choosing to participate in a study is an important decision we encourage you to discuss with your physicians, family members, and friends. Every study comes with potential risks and benefits you should discuss thoroughly with your physicians and study coordinators. Contact kelli@stopsarcoidosis.org to learn more.